Market capitalization | $31.20m |
Enterprise Value | $21.64m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.41 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-10.12m |
Free Cash Flow (TTM) Free Cash Flow | $-8.75m |
Cash position | $9.56m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a RenovoRx Inc forecast:
3 Analysts have issued a RenovoRx Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -10 -10 |
14%
14%
|
EBIT (Operating Income) EBIT | -10 -10 |
14%
14%
|
Net Profit | -9.16 -9.16 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. Its therapy platform, RenovoRx, handles the optimizing drug concentration in solid tumors using approved small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.
Head office | United States |
CEO | Shaun Bagai |
Employees | 8 |
Founded | 2009 |
Website | www.renovorx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.